ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Study: Brain Training Improves Cognitive Function In Multiple Sclerosis

SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- A study conducted at the University of Nebraska Medical Center showed use of a commercially-available brain training app significantly improved cognitive function in patients with Multiple Sclerosis (“MS”). The brain training used in the study was BrainHQ from Posit Science.

Nearly one million Americans, and 2.8 million people worldwide, are estimated to have MS — a chronic autoimmune, inflammatory, and neurodegenerative disorder of the central nervous system. While often associated with motor control issues, MS also commonly includes cognitive and neurological challenges. Diminished speed of information processing, which can affect both movement and cognition, is one of the most common cognitive deficits.

The study enrolled 53 adults (aged 19-60) and randomized them into either (A) an intervention group using BrainHQ for a total of nine hours spread over 6 weeks (30 minutes, three times weekly) or (B) an active control group, using online casual games on the same time schedule. One subject withdrew the day training began. The primary outcome measure was the Brief International Cognitive Assessment for MS (BICAMS), which includes three subtests: the Symbol Digit Modalities Test (SDMT), the Brief Visuospatial Memory Test – Revised (BVMT-R), and the initial learning trials of the California Verbal Learning Test 2nd Edition (CVLT-II).

The independent researchers reported significant improvement in the intervention group (as compared to the control) in the BICAMS, as well as in each of its three sub-tests.

They also reported high adherence, with 92 percent completing all levels of brain exercise assigned.

These results confirm and extend findings in prior studies of cognitive training in MS, including seven prior studies using BrainHQ. This is the first study to show significant improvements in BICAMS and each of its sub-tests.

The study report concludes: “This study provides evidence that computerized cognitive training with BrainHQ is a valuable option for [people with MS] suffering from cognitive decline. It is convenient for the patient because they can do it at home when they have time and not at a specific time with a neuropsychologist.”

“These are very exciting results from independent researchers,” Dr. Henry Mahncke, CEO of Posit Science, observed. “It makes sense that our exercises, shown in studies to improve speed of processing and myelination, would have an impact in a condition characterized by speed of processing deficits and de-myelination. We hope this spurs not just further research, but targeted chronic care improvement programs at leading medical centers and health plans to help patients in need.”

BrainHQ has shown benefits in hundreds of studies. Such benefits include gains in cognition (attention, speed, memory, decision-making), in quality of life (depressive symptoms, confidence and control, health-related quality of life) and in real-world activities (health outcomes, balance, driving, hearing). BrainHQ is offered, without charge, by leading national and 5-star Medicare Advantage plans and by leading medical centers, clinics, and communities. Consumers can try a BrainHQ exercise for free daily at https://www.brainhq.com.


Contact: media@brainhq.com

Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  243.40
-3.07 (-1.25%)
AAPL  259.97
-0.28 (-0.11%)
AMD  217.87
+10.18 (4.90%)
BAC  55.05
-0.14 (-0.26%)
GOOG  336.54
+3.81 (1.15%)
META  626.38
-15.59 (-2.43%)
MSFT  467.83
-9.35 (-1.96%)
NVDA  184.21
-0.73 (-0.40%)
ORCL  201.88
-2.80 (-1.37%)
TSLA  449.96
+1.00 (0.22%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.